August 3, 2006 -- Biogen Idec signed a deal with Amorfix for a potential therapy for ALS; Amgen won a patent ruling that governs its Epogen anemia drug; ThermoGenesis extended its agreement with Biomet; Palatin and King Pharma reported positive results from a sexual arousal disorder drug; Merck won a lawsuit in California against a patient who used Vioxx only sporadically; Galaapagos signed a deal with AstraZeneca to discover respiratory and inflammatory drugs; and CoTherix fell after it missed analysts’ second quarter estimates. The Centient Biotech 200™ gained 18 points to end at 3695.61. More details...
